Dr. Melinda Telli, Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine, is Director of the Breast Cancer Program at the Stanford Cancer Institute and Associate Director of the Stanford Women’s Cancer Center. Dr. Telli’s research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Dr. Telli currently serves as a Komen Scholar, Co-Chair of the American Society of Clinical Oncology Guideline Advisory Group, member of the National Comprehensive Cancer Network Breast Cancer Guideline Panel, member of the Journal of Clinical Oncology Editorial Board and Fellow of the American Society of Clinical Oncology.